马来酸桂哌齐特

马来酸桂哌齐特用途

1.脑血管疾病：脑动脉硬化、一过性脑缺血、脑血栓、脑栓塞、脑出血及脑外伤后遗症。
2.心血管疾病，用于动脉硬化、心绞痛，心肌梗塞患者应配合相关药物治疗。
3.眼底血管性疾病、缺血所致耳蜗前庭功能失调、突发性耳聋、耳鸣。
4.糖尿病引起的微循环障碍（糖尿病足、糖尿病视网膜病变等）。
5.其它外周血管性疾病:血栓闭塞性脉管炎、动脉炎、雷诺氏病、下肢动脉粥样硬化等。

马来酸桂哌齐特名称

[ CAS 号 ]:
26328-04-1

[ 中文名 ]:
马来酸桂哌齐特

[ 英文名 ]:
Cinepazide maleate

[中文别名 ]:

马来酸桂哌齐特

[英文别名 ]:

Cinepazide Mateate
brendil
MFCD01320526
EINECS 247-613-1
DD-3357
maleatedecinepazide
vasodistal
Cinepazide (Maleate)

马来酸桂哌齐特生物活性

[ 描述 ]:

Cinepazide马来酸盐是血管扩张剂。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 心血管疾病

[参考文献]

[1]. Akashi, A., et al., [Cardiovascular pharmacology of cinepazide, a new cerebral vasodilator (author's transl)]. Nihon Yakurigaku Zasshi, 1979. 75(5): p. 507-16.

[2]. Muramatsu, I., et al., Effects of cinepazide on the purinergic responses in the dog cerebral artery. Pharmacology, 1984. 28(1): p. 27-33.

[相关活性小分子]

马来酸桂哌齐特物理化学性质

[ 密度 ]:
1.256

[ 沸点 ]:
637.8ºC at 760 mmHg

[ 熔点 ]:
173 °C(dec.)

[ 分子式 ]:
C₂₆H₃₅N₃O₉

[ 分子量 ]:
533.57100

[ 闪点 ]:
339.5ºC

[ 精确质量 ]:
533.23700

[ PSA ]:
146.15000

[ LogP ]:
1.01770

[ 外观性状 ]:
白色或灰白色结晶粉末

[ 蒸汽压 ]:
3.65E-16mmHg at 25°C

[ 储存条件 ]:
-20°C

马来酸桂哌齐特毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TM2785100

CHEMICAL NAME :: Piperazine, 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3',4',5'-trimet hoxycinnamoyl)-, maleate

CAS REGISTRY NUMBER :: 26328-04-1

LAST UPDATED :: 199309

DATA ITEMS CITED :: 13

MOLECULAR FORMULA :: C22-H31-N3-O5.C4-H4-O4

MOLECULAR WEIGHT :: 533.64

WISWESSER LINE NOTATION :: T6N DNTJ AV1U1R CO1 DO1 EO1& D1V- AT5NTJ &QV1U1VQ -C

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1310 mg/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic

REFERENCE :: THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 710 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,407,1979

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 414 mg/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic

REFERENCE :: THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic

REFERENCE :: THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 946 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,407,1979

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 617 mg/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic

REFERENCE :: THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 62400 mg/kg/26W-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - other changes Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 17,83,1979 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 672 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,559,1979

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 16800 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - physical

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,559,1979

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 240 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,546,1979

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 10600 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,546,1979

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 312 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,572,1979

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 910 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,572,1979

马来酸桂哌齐特安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302

[ 警示性声明 ]:
P301 + P312 + P330

[ 危害码 (欧洲) ]:
Xi

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ 海关编码 ]:
2942000000

马来酸桂哌齐特制备

1. 3,4,5-三甲氧基肉桂酰氯的制备

在反应瓶中加入3,4,5-三甲氧基肉桂酸2.3g(9.8mmol)和环己烷10ml,搅拌悬浮,搅拌下滴加氯化亚砜7.2g,滴加时控制温度不超过20ºC,加毕,搅10min.室温放置过夜.低于50ºC,减压蒸除氯化亚砜,加入环己烷2.4ml重蒸一次,溶于6ml二氯甲烷中备用.

2. 1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪的制备

在反应瓶中加入(1-四氢吡咯羰基)甲基哌嗪1.6g(8.1mmol)和二氯甲烷16ml,搅拌溶解,冰浴冷却及搅拌下滴加上步含3,4,5-三甲氧基肉桂酰氯的二氯甲烷溶液,滴加过程保持内温10 ºC,加毕,室温搅拌4h.加入水10ml,充分振摇.分出水层,有机层加入15%盐酸10ml,充分振摇.将两次水层合并,用5%NaOH溶液中和至pH9~10.二氯甲烷(10ml×3)提取,合并有机层,饱和NaCl水溶液(10ml×2)洗,无水Na2SO4干燥过夜.过滤,滤液减压蒸除回收溶剂#得到棕色黏稠剩余物1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪2.34g,收率69.4%.

3. 1-[(1-四氢吡咯羰基)甲基]-4(3,4,5-三甲氧基肉桂酰基)哌嗪马来酸盐(马来酸桂哌齐特)的合成

在反应瓶中加入1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪0.42g(1.006mol)和无水乙醇4.4ml,搅拌溶解.在另一反应瓶中加入马来酸0.14g(1.2mmol)和无水乙醇0.6ml,搅拌溶解,然后加1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪的无水乙醇溶液,室温搅拌10min后,静置6h.得到1-[(1-四氢吡咯羰基)甲基]-4(3,4,5-三甲氧基肉桂酰基)哌嗪马来酸盐(马来酸桂哌齐特)0.27g色结晶,收率51.9%,mp130~132 ºC.

马来酸桂哌齐特海关

[ 海关编码 ]: 2942000000

马来酸桂哌齐特文献

An Improved Synthesis of Cinepazide Maleate. LIU, Hua-xiang, et al.

Fine Chemicals 10 , 012, (2009)

更多文献